Clinical impact of subcutaneous treprostinil in trisomy 21 patient with pulmonary arterial hypertension associated with CHD
Ryusuke Numata, Kiyohiro Takigiku, Kouta TakeiNagano Children’s HospitalJapan Cardiology in the YoungCardiol Young 2022; DOI: 10.1017/S1047951121005096 AbstractSubcutaneous treprostinil is commonly used to improve idiopathic pulmonary arterial hypertension in children. However, its effectiveness has not been reported in trisomy 21. We report the case of 9-year-old boy in trisomy 21 with CHD-pulmonary artery hypertension after surgical correction […]